Penn Medicine News
A targeted therapy that has shown its power in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
Basser Young Leadership Council Co-Chair Erika Stallings contributed this opinion piece to Huffington Post on the future of BRCA testing and on-going challenges, such as difficulties regarding access to genetic counseling and testing.
Penn Medicine News
Genetic counseling for cancer patients has become standard of care at academic medical centers. Video and phone sessions can bring genetic counseling to patients who would not otherwise have the chance to receive it, according to a new study from the Basser Center.
Basser founders Mindy and Jon Gray are featured in a Bloomberg Markets article profiling people in finance who have defined their philanthropy early in their careers.
Forbes spoke with Susan Domchek, MD, Executive Director of the Basser Center, about how a woman with advanced breast cancer might choose among treatment options, and the latest data available on the effectiveness and safety of PARP inhibitors.
Penn Medicine News
Penn Medicine researchers, including Basser's Roger Greenberg, PhD, MD, have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer.
In an op-ed about direct-to-consumer BRCA testing, Susan Domchek, MD, says that while genetic testing can be lifesaving, it must come with all the facts.
New York Times
The FDA approved at-home genetic testing for BRCA mutations, while highlighting concerns. Susan Domchek, MD, cautioned that people may experience anxiety when undergoing genetic testing, and recommends that they discuss any concerns with their doctor.
The BRCA Founder Outreach (BFOR) study, focusing on individuals of Ashkenazi descent, will give participants the opportunity to receive simpler access to genetic testing.
Healthline reports on recent research showing that many women who experience a bloating feeling on a regular basis are more likely to change their diets than visit their doctors, and in some cases, that could put women at risk of overlooking ovarian cancer symptoms.
Basser Young Leadership Council co-chair Erika Stalings reveals her experiences with dating after undergoing a preventive double mastectomy, and her struggles to decide if and when to tell dates about the surgery and her BRCA mutation status.
Susan M. Domchek, MD, Executive Director of the Basser Center, discusses the role biomarkers have in the treatment of patients with breast cancer. Identifying biomarkers in patients early on, such as knowledge of estrogen receptor status, can lead to better treatment plans, Domchek says.
Genetic counselors, oncologists and other experts are urging consumers to do their homework before sending in saliva samples and allowing their DNA to be screened for certain cancer risks by the company 23andMe.
U.S. consumers soon will be able to test themselves at home for some genetic mutations that increase the risk of breast, ovarian and prostate cancer — but you might want to think before you spit. Susan Domchek, MD, speaks to USA Today about BRCA mutations.
The FDA approved the first oral treatment for breast cancer patients who have inherited mutations in their BRCA genes. Susan Domchek, MD, who was involved in the clinical trial, discusses how this is a major step forward.
Penn Medicine Magazine
Penn Medicine Magazine's latest issue includes the story of how the Basser Center was founded in memory of Faith Basser, and how BRCA mutations can impact families around the world.
The U.S. Food and Drug Administration recently approved olaparib as the first treatment for advanced breast cancer caused by mutations in BRCA genes, in an important step in the fight against inherited cancers.